Sentinel ganglion in breast cancer: selective biopsy compared with axillary lymphadectomy
DOI:
https://doi.org/10.23938/ASSN.0134Keywords:
Ganglio centinela. Cáncer de mama. Linfogammagrafía. Supervivencia global. Supervivencia libre de enfermedad.Abstract
Background. Selective biopsy of the sentinel ganglion (SBSG) has replaced axillary lymphadectomy (AL) as the procedure of choice in staging breast cancer in its initial stages and in clinically negative axilla. The aim of this study is to compare global event-free survival of those patients subjected to SBSG followed by AL, during the period of validation of the technique, with respect to those subjected to SBSG and AL if the sentinel ganglion (SG) showed metastasis. Methods. One hundred and forty-eight patients were included, 81 belonging to the period of validation and 67 to the clinical application group. Radiocoloid was administered intraperitumorally, obtaining images up until the visualisation of the SG; its identification and extirpation were carried out subsequently in the surgical intervention. Results. The efficacy of the technique in the validation group was 92.5%, sensitivity was 95.6% and the rate of false negatives was 4%. Of the 81 patients, 75 are free of disease (92.6%). Of the 67 patients belonging to the clinical application group, 63 (94%) are free of disease. No patient has presented axillary ganglion recurrence. Conclusion. In the validation of the technique we obtained values that fall within the demands of generally accepted quality. With an average follow up of 6 years we did not observe axillary ganglion recurrence in any of the two groups. There is no statistically significant difference in global and event free survival between the two groups.Downloads
References
1. KRAG DN, WEAVER DL, ALEX JD, FAIRBANK JT. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335-349.
https://doi.org/10.1016/0960-7404(93)90064-6
2. GIULIANO AE, DIRGAN DM, GUENTHER M, MORTON DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-401.
https://doi.org/10.1097/00000658-199409000-00015
3. MORTON DL, WEN DR, WONG JH, ECONOMOU JS, CAGLE LA, STORM FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
https://doi.org/10.1001/archsurg.1992.01420040034005
4. LYMAN GH, GIULIANO AE, SOMERFIELD MR, BENSON III AB, BODURKA DC, BURSTEIN HJ et al. American society of clinical oncology guideline. Recommendations for sentinel node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-7720.
https://doi.org/10.1200/JCO.2005.08.001
5. SCHWARTZ GF, GIULIANO AE, VERONESI U and the Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94: 2542-2551.
https://doi.org/10.1002/cncr.10539
6. SENN HJ, THURLIMANN B, GOLDHIRSCH, WOOD WC, GELBER RD, COATES AS. Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer. Breast 2003; 12: 569-582.
https://doi.org/10.1016/j.breast.2003.09.007
7. MABRY H, GIULIANO AE. Sentinel node mapping for breast cancer: progress to date and prospects for the future. Surg Oncol Clin N Am 2007; 16: 55-70.
https://doi.org/10.1016/j.soc.2006.10.015
8. FANT JS, GRANT MD, KNOX SM, LIVINGSTON SA, RIDL K, JONES RC et al. Preliminary outcome analysis in patients with breast cancer and positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol 2003; 10: 126-130.
https://doi.org/10.1245/ASO.2003.04.022
9. MANSEL RE, FALLOWFIELD L, KISSIN M, GOYAL A, NEWCOMBE RG, DIXON JM et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006; 98: 599-609.
https://doi.org/10.1093/jnci/djj158
10. VICENTE F, MIRANDA MC, MARTÍNEZ-PEÑUELA JM, MARTÍNEZ E, LERA JM. Ganglio centinela en carcinoma de mama: situación actual. Criterios de actuación en el Hospital de Navarra. An Sist Sanit Navar 2001; 24: 363-367.
11. Ganglio centinela y cáncer de mama. Reunión Nacional de Consenso de Salamanca. Rev Esp Med Nuclear 2002; 21: 77-79.
https://doi.org/10.1016/S0212-6982(02)72037-5
12. CÓRDOBA A, EDERRA M, AMAT I, BELOQUI R, MIRANDA C, ZOZAYA E et al. Ganglio centinela en cáncer de mama. Estudio histológico de 67 casos. An Sist Sanit Navar 2004; 27: 191-200.
https://doi.org/10.4321/S1137-66272004000300004
13. SINGLETARY SE, ALLRED C, ASHLEY P, BASSETT LW, BERRY D, BLAND KL et al. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
https://doi.org/10.1200/JCO.2002.02.026
14. GUILIANO AE, JONES RC, BRENNAN M, STATMAN R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15: 2345-2350.
https://doi.org/10.1200/JCO.1997.15.6.2345
15. KRAG D, WEAVER D, ASHIKAGA T, MOFFAT F, KLIMBERG VS, SHRIVER C et al. The sentinel node in breast cancer. A multicenter validation study. N Engl J Med 1998; 339: 941-946.
https://doi.org/10.1056/NEJM199810013391401
16. VERONESI U, PAGANELLI G, VIALE G, GALIMBERTI V, LUINI A, ZURRIDA S et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91: 368-373.
https://doi.org/10.1093/jnci/91.4.368
17. MILTENBURG DM, MILLER C, KARAMLOU TB, BRUNICARDI FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999; 84: 138-142.
https://doi.org/10.1006/jsre.1999.5629
18. HARLOW SP, KRAG DN, JULIAN TB, ASHIKAGA T, WEAVER DL, FELDMAN SA et al. Prerandomization surgical training for the national adjuvant breast and bowel proyect (NSABP). A randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinical node negative breast cancer. Ann Surg 2005; 241: 48-54.
https://doi.org/10.1097/01.sla.0000149429.39656.94
19. GOYAL A, NEWCOMBE RG, CHHABRA A, MANSEL RE, ALMANAC Trialists group. Factors affecting failed localization and false- negative rates of sentinel node biopsy in breats cancer-results of the ALMANAC validation phase. Breast Cancer Res Treat 2006; 99: 203-208.
https://doi.org/10.1007/s10549-006-9192-1
20. VERONESI U, GALIMBERTI V, PAGANELLI G, MAISONNEUVE P, VIALE G, ORECCHIA R et al. Axillary metastases in breast cancer patients with negative sentinell nodes: a follow-up of 3548 cases. Eur J Cancer 2009; 45: 1381-1388.
https://doi.org/10.1016/j.ejca.2008.11.041
21. CANAVESE G, CATTURICH A, VECCHIO C, TOMEI D, GIPPONE M, VILLA G et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 2009; 20: 1001-1007.
https://doi.org/10.1093/annonc/mdn746
22. NAIK AM, FEY J, GEMIGNANI M, HEEROT A, MONTGOMERY L, PETREK J et al. Risk of axilary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. A follow-up of 4008 procedures. Ann Surg 2004; 240:462-471.
https://doi.org/10.1097/01.sla.0000137130.23530.19
23. VAN DER PLOEG IM, NIEWEG OE, VAN RIJK MC, VALDÉS OLMOS RA, KROON BB. Axillary recurence after a tumor-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008; 34: 1277-1284.
https://doi.org/10.1016/j.ejso.2008.01.034
24. TORRENGA H, FABRY H, VAN DER SIJP JR, VAN DIEST PJ, PIJPERS R, MEIJER S. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 2004; 88: 4-7.
https://doi.org/10.1002/jso.20101
25. SMIDT ML, JANSSEN CM, KUSTER DM, BRUGGINK ED, STROBBE LJ. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005; 12: 29-33.
https://doi.org/10.1007/s10434-004-1166-0
26. LANGER I, MARTI WR, GULLER U, MOCH H, HARDER F, OERTLI D et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometatases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005; 241: 152-158.
https://doi.org/10.1097/01.sla.0000149305.23322.3c
27. KUIJT GP, VAN DE POLL-FRANSE LV, VOOGD AC, NIEUWENHUIJZEN GA, ROUMEN RM. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after extensive axillary dissection. Eur J Surg Oncol 2007; 33: 832-837.
https://doi.org/10.1016/j.ejso.2006.11.017
28. LANGER I, GULLER U, HSU-SCHMITZ SF, LADEWIG A, VIEHL CT, MOCH H et al. Sentinel lymphnode biopsy is associated with improved survival compared to level I y II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 2009; 35: 805-813.
https://doi.org/10.1016/j.ejso.2008.09.006
29. ZAVAGNO G, DE SALVO GL, SCALCO G, BOZZA F, BARUTTA L, DEL BIANCO P et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary node dissection in breast cancer. Results of the sentinella/GIVOM trial. Ann Surg 2008; 247: 207-213.
https://doi.org/10.1097/SLA.0b013e31812e6a73
30. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
https://doi.org/10.1016/S0140-6736(05)66544-0
31. SAPHNER T, TORMEY DC GRAY R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
